11:17 AM EDT, 06/26/2024 (MT Newswires) -- Cyclacel Pharmaceuticals ( CYCC ) said Wednesday the European Patent Office has notified the company of its intention to grant a patent for plogosertib, which is being studied for cancer treatment.

The patent covers claims to pharmaceutical compositions of the PLK1 inhibitor and supports a switch to a new oral formulation with improved bioavailability, and is expected to be valid until August 2040, the company said.

Cyclacel shares were 9% higher in recent trading.

Price: 1.73, Change: +0.14, Percent Change: +8.81